Latest QurAlis News & Updates

See the latest news and media coverage for QurAlis. We track all announcements, press releases, and industry mentions in real time, all in one place.

QurAlis

Biotechnology company developing neurodegenerative disease therapies

quralis.com

Headquarters: Cambridge, United States
Founded year: 2016
Company type: Private company
Number of employees: 77–200
Industry: Pharmaceuticals

Last updated May 6

Latest news about QurAlis

In short: QurAlis reported positive QRL-201 interim data and advanced ALS and Fragile X partnerships.

Company announcements

May 6 QurAlis

QurAlis shares updated interim data from ANQUR trial

Data shows dramatic slowing of disease in sporadic ALS patients, presented by CEO Kasper Roet at Target ALS Annual Meeting.

February 23 QurAlis

QurAlis announces positive interim ANQUR trial data for QRL-201

Data show target engagement, STMN2 restoration, neurofilament reduction, and slowed ALS progression. Plans advance to Phase 3 in 2027.

December 29, 2025 QurAlis

QurAlis announces topline data from QRL-101-04 trial

Results demonstrate first evidence of target engagement with selective Kv7.2/7.3 ion channel opener in ALS patients. CEO highlights validating research.

March 12, 2025 QurAlis

QurAlis announces positive topline data from QRL-101 Phase 1 trial

Results show significant biomarker effects for ALS and epilepsy, brain penetration, and good safety profile. Plans proof-of-concept studies.

Media coverage

February 25 ALS News Today

Experimental ALS therapy QRL-201 shows potential to slow disease decline

Experimental therapy QRL-201 shows potential to slow ALS progression by restoring a vital nerve protein. Interim Phase 1/2 data indicate that QRL-201 restores Stathmin-2 levels...

February 23 BioSpace

QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS

First clinical development program in sporadic ALS patients to show potential to restore STATHMIN-2 expression, a statistically significant effect on a neurofilament biomarker, and an...

February 21 Endpoints News

QurAlis’ ALS drug sees early positive signal, but questions remain

QurAlis believes the biomarker data from the Phase 1/2 study are strong enough to move QRL-201 to a pivotal trial. But the experiment failed to...

June 4, 2024 PharmaBiz

QurAlis grants Eli Lilly global rights to develop & commercialise QRL-204, a potentially first-in-class precision therapy that restores UNC13A function in ALS & FTD

QurAlis Corporation (QurAlis) announced that it has entered into an exclusive license agreement with Eli Lilly and Company (Lilly) in which QurAlis is granting Lilly...

Never miss news about QurAlis

Track QurAlis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

QurAlis competitors & trending companies

Browse news for competitors to QurAlis and other trending companies.